

- **Full Name :** Benjamin Besse
- **Current Position & Affiliation :** Head of Clinical Research – Gustave Roussy
- **Country :** France

---

• **Educational Background:**

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/ YY	FIELD OF STUDY
Paris V Medical School	M.D.	10/05	Medicine, Medical Oncology
Paris Saclay University	Ph.D.	10/08	Basis of oncogenesis
Paris Saclay University	Habilitation to conduct researches	12/16	Predictive biomarkers

• **Professional Experience:**

- Since 09/2021: Head of Clinical Research, Gustave Roussy
- 02/2018 – 08/2021: Head of Department of Cancer Medicine, Gustave Roussy
- Since 09/2017: Full professor of Medical Oncology, Paris-Saclay University, Orsay
- 09/2009 - 01/2018: Head of the Thoracic Tumor Group, Gustave Roussy
- 06/2007- 08/2009: Associate Professor of Medicine, Gustave Roussy
- 11/2005-10/2007: Assistant Professor of Medicine, Gustave Roussy and Paris-Saclay University
- 2003-2007: Doctoral Fellow, Institute Catalan de Oncologia, Barcelona and Paris-Saclay University
- 1999-2005: Resident and Fellow, Medical Oncology Program, Assistance Publique-Hôpitaux de Paris

• **Professional Organizations:**

- Gustave Roussy Cancer Center, Villejuif, France
- Paris-Saclay University, Orsay, France
- French National Thymic Malignancies Network (RYTHMIC): fundator and chair of the since 2010.
- European Organisation for Research and Treatment of Cancer (EORTC): Chair of the EORTC Scientific Chairs Council since 2020, Chair of the Lung Cancer Group (2015 to 2020)

• **Main Scientific Publications:**

1. Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M, Hochstenbag M, Hendriks LEL, **Besse B**. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. Eur J Cancer. 2022 Dec 12;180:117-124.
2. Boulate D, Fidelle M, Caramella C, Issard J, Planché O, Pradère P, Garelik D, Hache O, Lamrani L, Zins M, Beaussier H, Chatellier G, Fadel E, Zitvogel L, **Besse B**, Mercier O. Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-

- associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol. *BMJ Open*. 2022 Dec 26;12(12):e067191.
- Boileve A, Albiges L, Ducreux M, Baudin E, Leary A, **Besse B**, Hadoux J, Malka D, Rieutord A, Scotté F, Maulard A, Mir O. Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study. *Support Care Cancer*. 2022 Dec 16;31(1):41.
  - Drilon A, Horan JC, Tangpeerachaiikul A, **Besse B**, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. *Cancer Discov*. 2022 Dec 13:CD-22-0968.
  - Camard M, **Besse B**, Cariou PL, Massayke S, Laparra A, Noel N, Michot JM, Ammari S, Pavec JL, Lambotte O. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. *Respir Med Res*. 2022 Nov;82:100969.
  - Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, **Besse B**, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. *Eur J Cancer*. 2022 Dec;177:175-185.
  - Aldea M, Belkhir R, Colomba E, Blanchard P, Danlos FX, Botticella A, Terlizzi M, Deutsch E, Le Péchoux C, Planchard D, Michot JM, **Besse B**, Levy A. Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report. *Front Immunol*. 2022 Oct 24;13:920130.
  - Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoué-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. *Sci Rep*. 2022 Nov 9;12(1):19055.
  - Martin-Romano P, Mezquita L, Hollebecque A, Lacroix L, Rouleau E, Gazzah A, Bahleda R, Planchard D, Varga A, Baldini C, Postel-Vinay S, Friboulet L, Lorient Y, Verlingue L, Geraud A, Camus MN, Nicotra C, Soria JC, André F, **Besse B**, Massard C, Italiano A. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. *JCO Precis Oncol*. 2022 Oct;6:e2100484.
  - Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, **Besse B**, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot JM, Massard C, Mezquita L. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. *Cancers (Basel)*. 2022 Oct 17;14(20):5078.
  - Henry T, Sun R, Lerousseau M, Estienne T, Robert C, **Besse B**, Robert C, Paragios N, Deutsch E. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies. *Sci Rep*. 2022 Oct 14;12(1):17244.
  - Mordant P MD, PhD, Brosseau S, Milleron B, Santelmo N, Fraboulet-Moreau S, **Besse B**, Langlais A, Gossot D, Thomas PA, Pujol JL, Ricordel C, Madelaine J, Lamy R, Audigier-Valette C, Missy P, Blons H, Barlesi F, Westeel V; French Cooperative Thoracic Intergroup (IFCT). Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. *Clin Lung Cancer*. 2023 Jan;24(1):1-10.

13. Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Martin Romano P, Ngo Camus M, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, **Besse B**, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). *Ann Oncol.* 2022 Dec;33(12):1328-1331.
14. Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, **Besse B**. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. *J Clin Oncol.* 2022 Sep 19;JCO2200393.
15. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, **Besse B**, Peters S; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIa non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol.* 2022 Oct;23(10):1274-1286.
16. Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, **Besse B**, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, On Behalf Of The Esmo Co-Care. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. *Cancers (Basel).* 2022 Aug 16;14(16):3931.
17. Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, **Besse B**, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. *Cancer Treat Rev.* 2022 Nov;110:102452.
18. Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, **Besse B**, Su W, Chao BH, Drilon A. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIa RET fusion-positive non-small-cell lung cancer. *Future Oncol.* 2022 Sep;18(28):3133-3141.
19. Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupert M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, Archambaud B, Belhechmi S, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, Le Teuff G, Derosa L,

- Marabelle A, Van Dorp J, Van Dijk N, Van Der Heijden MS, **Besse B**, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y. Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. *Cancer Discov.* 2022 Oct 5;12(10):2280-2307.
20. Presti D, Dall'Olio FG, **Besse B**, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review. *Crit Rev Oncol Hematol.* 2022 Sep;177:103773.
21. Lambert T, Pobel C, Colmet-Daage L, Bigorgne A, Rauby Y B, Aladro NS, Ter-Minassian N L, Kerisit M, Marabelle A, **Besse B**, Hollebecque A, Champiat S, Massard C, Morel D, Verlingue L, Scoazec JY. Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. *Cancer Treat Res Commun.* 2022;32:100611.
22. Peyraud F, Guégan JP, Bodet D, Nafia I, Fontan L, Auzanneau C, Cousin S, Roubaud G, Cabart M, Chomy F, Le Loarer F, Chaput N, Danlos FX, Planchard D, Even C, Khettab M, Tselikas L, **Besse B**, Barlesi F, Soria JC, Marabelle A, Bessede A, Italiano A. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. *Ann Oncol.* 2022 Oct;33(10):1041-1051.
23. Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, **Besse B**, Ferrara R, Chaput N, Baldini C. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. *Expert Rev Anticancer Ther.* 2022 Sep;22(9):915-926.
24. Riudavets M, Garcia de Herreros M, **Besse B**, Mezquita L. Radon and Lung Cancer: Current Trends and Future Perspectives. *Cancers (Basel).* 2022 Jun 27;14(13):3142.
25. Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy F, Souquet PJ, Cloarec N, Giroux-Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, **Besse B**. Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial. *Clin Cancer Res.* 2022 Sep 15;28(18):4018-4026.
26. Vasseur D, Sassi H, Bayle A, Tagliamento M, **Besse B**, Marzac C, Arbab A, Auger N, Cotteret S, Aldea M, Blanc-Durand F, Géraud A, Gazzah A, Loriot Y, Hollebecque A, Martín-Romano P, Ngo-Camus M, Nicotra C, Ponce S, Sakkal M, Caron O, Smolenschi C, Micol JB, Italiano A, Rouleau E, Lacroix L. Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. *Cells.* 2022 Jun 11;11(12):1901.
27. Pilotto S, Avancini A, Menis J, Sperduti I, Giaj Levra M, Berghmans T, Bironzo P, Brandão M, De Ruyscher D, Edwards J, Faivre-Finn C, Girard N, Greillier L, Hendriks L, Lantuejoul S, Mauer M, Novello S, O'Brien M, Reck M, Reguart N, Remon J, von der Thüsen J, Dingemans AC, **Besse B**, Milella M. Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. *Lung Cancer.* 2022 Jul;169:94-101.
28. Riudavets M, Lamberts V, Vasseur D, Auclin E, Aldea M, Jovelet C, Naltet C, Lavaud P, Gazzah A, Aboubakar F, Dorta M, Remon J, Rouleau E, Ngocamus M, Nicotra C, Lacroix L, **Besse B**, Mezquita L, Planchard D. Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer.* 2022 Sep;23(6):e377-e383.
29. Larroquette M, Guegan JP, **Besse B**, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Spatial transcriptomics

- of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. *J Immunother Cancer*. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. PMID: 35618288 Free PMC article.
30. Mogenet A, Barlesi F, **Besse B**, Michiels S, Karimi M, Tran-Dien A, Girard N, Mazieres J, Audigier-Valette C, Locatelli-Sanchez M, Kamal M, Gestraud P, Hamza A, Jacquet A, Jimenez M, Yara S, Greillier L, Bertucci F, Planchard D, Soria JC, Bieche I, Tomasini P. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. *Lung Cancer*. 2022 Jul;169:31-39.
  31. Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, **Besse B**, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Frost H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Huddar P, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Rogado J, Romano E, Rowe M, Sekacheva M, Sheehan R, Stevenson J, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Palmieri C, Landers D, Cooksley T; ESMO Co-Care, Dive C, Freitas A, Armstrong AC. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. *JCO Clin Cancer Inform*. 2022 May;6:e2100177.
  32. Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss EL, Govindan R, Tan IB, Yap YS, Robinson WA, Morris CD, **Besse B**, Bardelli A, Tie J, Kopetz S, Rosenfeld N. Liquid biopsies for residual disease and recurrence. *Med (N Y)*. 2021 Dec 10;2(12):1292-1313.
  33. Morfouace M, Novello S, Stevovic A, Doms C, Janžič U, Berghmans T, Dziadziuszko R, Gorlia T, Felip E, Paz-Ares L, Mazieres J, O'Brien M, Bironzo P, Vansteenkiste J, Lacroix L, Dingemans AC, Golfopoulou V, **Besse B**. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTALung platform. *Sci Rep*. 2022 May 18;12(1):8342.
  34. Tayoun T, Faugeron V, Oulhen M, Déas O, Michels J, Brulle-Soumare L, Cairo S, Scoazec JY, Marty V, Aberlenc A, Planchard D, Remon J, Ponce S, **Besse B**, Kannouche PL, Judde JG, Pawlikowska P, Farace F. Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants. *JCI Insight*. 2022 Jun 8;7(11):e155804.
  35. Tagliamento M, Frelaut M, Baldini C, Naigeon M, Nencioni A, Chaput N, **Besse B**. The use of immunotherapy in older patients with advanced non-small cell lung cancer. *Cancer Treat Rev*. 2022 May;106:102394.
  36. Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar SN, Pepin K, Ward JP, Botticella A, Howarth K, Knape C, Morris C, Govindan R, **Besse B**, Morgensztern D. Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. *Front Oncol*. 2022 Mar 28;12:856132.
  37. Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalzman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V,

- Campayo M, Recondo G, **Besse B**, Planchard D, Mezquita L. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. *Eur J Cancer*. 2022 May;167:142-148.
38. Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, **Besse B**; ANSELMA collaborative group. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. *Eur J Cancer*. 2022 May;166:112-125.
39. Baldacci S, **Besse B**, Avrillon V, Mennequier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clément-Duchêne C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. *Eur J Cancer*. 2022 May;166:51-59.
40. Girard N, Galland-Girodet S, Avrillon V, **Besse B**, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. *ESMO Open*. 2022 Apr;7(2):100418.
41. McCoach CE, Rolfo C, Drilon A, Lacouture M, **Besse B**, Goto K, Zhu VW, Tan DSW, Farajian S, Potter LA, Kherani JF, Soldatenkova V, Olek EA, Muehlenbein CE, Park K. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. *J Thorac Oncol*. 2022 Jun;17(6):768-778.
42. Dall'Olio FG, Parisi C, Marcolin L, Brocchi S, Caramella C, Conci N, Carpani G, Gelsomino F, Ardizzoni S, Marchese PV, Paccapelo A, Grilli G, Golfieri R, **Besse B**, Ardizzoni A. Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC. *Ther Adv Med Oncol*. 2022 Feb 12;14:17588359211058391.
43. Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall'Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andriani E, Addeo A, Friedlaender A, Facchinetti F, Gorriá T, Mezquita L, Hoton D, Valerie L, Nana FA, Artingstall J, Comins C, Di Maio M, Caglio A, Cave J, McKenzie H, Newsom-Davis T, Evans JS, Tiseo M, D'Alessio A, Fulgenzi CAM, **Besse B**, Awad MM, Pinato DJ. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. *J Immunother Cancer*. 2022 Feb;10(2):e004374.
44. Duchemann B, Naigeon M, Auclin E, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Danlos FX, Mezquita L, Caramella C, Marabelle A, **Besse B**, Chaput N. CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. *J Immunother Cancer*. 2022 Feb;10(2):e004012.
45. Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, **Besse B**, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessedé A, Fridman WH, Loarer FL, Italiano A. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. *Nat Cancer*. 2021 Aug;2(8):794-802.

46. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, **Besse B**. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. *Nat Med*. 2022 Feb 3.
47. Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, **Besse B**. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. *J Clin Oncol*. 2022 Jan 24;JCO2101455.
48. Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Lorient Y, **Besse B**, Friboulet L. Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. *Ann Oncol*. 2022 Jan 20;S0923-7534(22)00009-6.
49. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, **Besse B**, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease. *J Thorac Oncol*. 2022 Jan 10;S1556-0864(21)03417-1.
50. Lamy T, Cabarrou B, Planchard D, Quantin X, Schneider S, Bringuier M, **Besse B**, Girard N, Chouaid C, Filleron T, Simon G, Baldini C. Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. *Cancers (Basel)*. 2021 Dec 24;14(1):92.
51. Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Menecier B, Westeel V, Thillays F, Quantin X, Oulkhair Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game L, **Besse B**, Girard N. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. *Eur J Cancer*. 2022 Feb;162:118-127.
52. Riudavets M, Naigeon M, Texier M, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, NgoCamus M, Lacroix L, Mezquita L, **Besse B**, Chaput N, Planchard D. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. *Lung Cancer*. 2021 Dec 3;S0169-5002(21)00624-3.
53. Molinier O, **Besse B**, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureauux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer. *ESMO Open*. 2021 Dec 22;7(1):100353.
54. Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, **Besse B**, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber JP, Altmüller J, Thomas RK, Merkelbach-Bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J, Scheffler M, Sos ML. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. *NPJ Precis Oncol*. 2021 Dec 17;5(1):102.
55. Doyen J, **Besse B**, Texier M, Bonnet N, Levy A. PD-1 inhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the

- Prospective Randomized Phase 3 NIRVANA-Lung Trial. *Clin Lung Cancer*. 2021 Oct 24:S1525-7304(21)00269-2.
56. Aldea M, Benitez JC, Chaput N, **Besse B**. New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma. *Cancer Discov*. 2021 Nov;11(11):2674-2676.
  57. Remon J, **Besse B**. Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better? *Nat Rev Clin Oncol*. 2021 Oct 27.
  58. Dall'Olivo FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, **Besse B**. Tumour burden and efficacy of immune-checkpoint inhibitors. *Nat Rev Clin Oncol*. 2021 Oct 12.
  59. Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, Zhang X, Graber A, Reich SH, Stopatschinskaja S, Solomon B, **Besse B**, Drilon A. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. *Mol Cancer Ther*. 2021 Oct 8.
  60. Remon J, Facchinetti F, **Besse B**. The efficacy of immune checkpoint inhibitors in thoracic malignancies. *Eur Respir Rev*. 2021 Oct 5;30(162):200387.
  61. Benitez JC, Geraud A, Texier M, Massard C, Paci A, Soria JC, **Besse B**. Late phase 1 studies: concepts and outcomes. *Lancet Oncol*. 2021 Oct;22(10):e446-e455.
  62. Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoun M, Cauquil C, Martin-Romano P, Baldini C, Laparra A, Vuagnat P, Hollebecque A, Mateus C, **Besse B**, Naltet C, Robert C, Marabelle A, Massard C, Lambotte O, Michot JM. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. *Eur J Cancer*. 2021 Nov;157:383-390.
  63. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. *Mol Oncol*. 2021 Oct;15(10):2507-2543
  64. Recondo G, Mahjoubi L, Maillard A, Lorient Y, Bigot L, Facchinetti F, Bahleda R, Gazzah A, Hollebecque A, Mezquita L, Planchard D, Naltet C, Lavaud P, Lacroix L, Richon C, Lovergne AA, De Baere T, Tselikas L, Deas O, Nicotra C, Ngo-Camus M, Frias RL, Solary E, Angevin E, Eggermont A, Olaussen KA, Vassal G, Michiels S, Andre F, Scoazec JY, Massard C, Soria JC, Besse B, Friboulet L. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. *NPJ Precis Oncol*. 2020 Sep 8;4(1):27.
  65. Malenica I, Adam J, Cognac S, Mezquita L, Auclin E, Damei I, Grynszpan L, Gros G, de Montpréville V, Planchard D, Théret N, Besse B, Mami-Chouaib F. Integrin- $\alpha$ V-mediated activation of TGF- $\beta$  regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. *Nat Commun*. 2021 Sep 1;12(1):5209.
  66. Planchard D, **Besse B**, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. *J Thorac Oncol*. 2021 Aug 26:S1556-0864(21)02403-5.
  67. Benitez JC, Boucher MÈ, Dansin E, Kerjouan M, Bigay-Game L, Pichon E, Thillays F, Falcoz PE, Lyubimova S, Oulkhair Y, Calcagno F, Thiberville L, Clément-Duchêne C,



- Westeel V, Missy P, Thomas PA, Maury JM, Molina T, Girard N, **Besse B**. Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC. *J Thorac Oncol*. 2021 Dec;16(12):2144-2149.
68. Cabanié C, Ammari S, Hans S, Pobel C, Laparra A, Danlos FX, Chanson N, Dolidon S, Seban R, Voisin AL, Pautier P, Romano-Martin P, Even C, Baldini C, **Besse B**, Albiges L, Boutros C, Routier E, Balleyguier C, De Montpreville VT, Champiat S, Massard C, Robert C, Marabelle A, Mateus C, Lambotte O, Le Pavec J, Michot JM. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. *Eur J Cancer*. 2021 Oct;156:46-59.
69. Loriot Y, Marabelle A, Guégan JP, Danlos FX, **Besse B**, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. *Ann Oncol*. 2021 Nov;32(11):1381-1390.
70. Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, **Besse B**, Awad MM, Pinato DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. *Ann Oncol*. 2021 Nov;32(11):1391-1399.
71. Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabé R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, **Besse B**. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. *Clin Lung Cancer*. 2021 Jul 20:S1525-7304(21)00189-3.
72. Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, **Besse B**, Massard C, Mezquita L, Hollebecque A. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. *Cancers (Basel)*. 2021 Jul 27;13(15):3776.
73. Auclin E, Mezquita L, **Besse B**. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. *Cancers (Basel)*. 2021 Jul 20;13(14):3624.
74. Naltet C, **Besse B**. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. *Transl Lung Cancer Res*. 2021 Jun;10(6):3014-3028.
75. Benitez JC, **Besse B**. Narrative review of immunotherapy in thymic malignancies. *Transl Lung Cancer Res*. 2021 Jun;10(6):3001-3013.
76. Duchemann B, Remon J, Naigeon M, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, Desnoyer A, **Besse B**, Chaput N. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. *Transl Lung Cancer Res*. 2021 Jun;10(6):2937-2954.
77. Hendriks LEL, Remon J, Menis J, **Besse B**. Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases? *Transl Lung Cancer Res*. 2021 Jun;10(6):2868-2875.
78. Remon J, **Besse B**. Immunotherapy in other thoracic malignancies and uncommon populations. *Transl Lung Cancer Res*. 2021 Jun;10(6):2865-2867.

79. Hendriks LEL, Remon J, **Besse B**. Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression. *Clin Lung Cancer*. 2021 Jun 12:S1525-7304(21)00149-2.
80. Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, Manaresi N, Aberlenc A, Mezquita L, Lecluse Y, Lavaud P, Naltet C, Planchard D, **Besse B**, Farace F. Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. *NPJ Precis Oncol*. 2021 Jul 16;5(1):67. doi: 10.1038/s41698-021-00203-1. PMID: 34272470 Free PMC article
81. Bayle A, Baldini C, Martin-Romano P, Michot JM, Champiat S, Bahleda R, Gazzah A, Marabelle A, Verlingue L, Geraud A, Morel D, Michiels S, Hollebecque A, Albiges L, **Besse B**, Soria JC, Massard C, Barlesi F, Postel-Vinay S. Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. *Cancer Cell*. 2021 Jun 18:S1535-6108(21)00332-9.
82. Delorme J, Charvet V, Wartelle M, Lion F, Thuillier B, Mercier S, Soria JC, Azoulay M, **Besse B**, Massard C, Hollebecque A, Verlingue L. Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. *JCO Clin Cancer Inform*. 2021 Jun;5:709-718.
83. Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression 50. *Future Oncol*. 2021 Jun 22.
84. Gainor JF, Curigliano G, Kim DW, Lee DH, **Besse B**, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol*. 2021 Jul;22(7):959-969.
85. Remon J, Hendriks LEL, **Besse B**. Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2021 Jun 8:JCO2100760.
86. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, **Besse B**, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. *N Engl J Med*. 2021 Jun 24;384(25):2371-2381.
87. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, **Besse B**, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. *Clin Cancer Res*. 2021 Jun 4.
88. Benitez JC, Campayo M, Díaz T, Ferrer C, Acosta-Plasencia M, Monzo M, Cirera L, **Besse B**, Navarro A. Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer. *J Pers Med*. 2021 May 16;11(5):420.
89. Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, **Besse B**. Predicting immunotherapy outcomes under therapy in patients with

- advanced NSCLC using dNLR and its early dynamics. *Eur J Cancer*. 2021 Jul;151:211-220.
90. Foy V, Lindsay CR, Carmel A, Fernandez-Gutierrez F, Krebs MG, Priest L, Carter M, Groen HJM, Hiltermann TJN, de Luca A, Farace F, **Besse B**, Terstappen L, Rossi E, Morabito A, Perrone F, Renehan A, Faivre-Finn C, Normanno N, Dive C, Blackhall F, Michiels S. EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. *Transl Lung Cancer Res*. 2021 Apr;10(4):1653-1665.
  91. Mihoubi Bouvier F, Thomas De Montpréville V, **Besse B**, Missenard G, Court C, Tordjman M, Le Pechoux C, Leroy Ladurie F, Balleyguier C, Fadel E, Caramella C. Can MRI differentiate surrounding vertebral invasion from reactive inflammatory changes in superior sulcus tumor? *Eur Radiol*. 2021 May 15.
  92. El Hazzaz R, Kfoury M, Lavaud P, Marabelle A, Champiat S, Mellas N, **Besse B**, Massard C, Geraud A. [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. *Bull Cancer*. 2021 Jun;108(6):635-642.
  93. Laparra A, Kfoury M, Champiat S, Danlos FX, Martin-Romano P, Simonaggio A, Baldini C, Vuagnat P, Mateus C, Voisin AL, Albiges L, **Besse B**, Even C, Robert C, Laghouati S, Massard C, Marabelle A, Lambotte O, Michot JM. Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials? *Ann Oncol*. 2021 Jul;32(7):936-937.
  94. Dingemans AC, Früh M, Ardizzoni A, **Besse B**, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruyscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021 Jul;32(7):839-853.
  95. Fenizia F, Wolstenholme N, Fairley JA, Rouleau E, Cheetham MH, Horan MP, Torlakovic E, **Besse B**, Al Dieri R, Tiniakos DG, Deans ZC, Patton SJ, Normanno N. Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path). *Virchows Arch*. 2021 Apr 15.
  96. Facchinetti F, Levy A, Ammari S, Naltet C, Lavaud P, Aldea M, Vasseur D, Planchard D, **Besse B**. Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. *Cancer Manag Res*. 2021 Mar 26;13:2805-2810.
  97. Epailard N, Benitez JC, Gorria T, Fabre E, Riudavets M, Reyes R, Planchard D, Oudard S, Viñolas N, Reguart N, **Besse B**, Mezquita L, Auclin E. Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. *Lung Cancer*. 2021 May;155:114-119.
  98. Bayle A, Droin N, **Besse B**, Zou Z, Boursin Y, Rissel S, Solary E, Lacroix L, Rouleau E, Borget I, Bonastre J. Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting. *Eur J Health Econ*. 2021 Aug;22(6):855-864.
  99. Remon J, Aldea M, **Besse B**, Planchard D, Reck M, Giaccone G, Soria JC. Small cell lung cancer: a slightly less orphan disease after immunotherapy. *Ann Oncol*. 2021 Jun;32(6):698-709.
  100. Basse C, Botticella A, Molina TJ, Falcoz PE, Oulkhair Y, Kerjouan M, Pichon E, Westeel V, Thiberville L, Quantin X, Clément-Duchêne C, Khalifa J, Tinier FL, Ginoux M, Thillays F, Mordant P, **Besse B**, Thomas PA, Péchoux CL, Girard N. RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. *Clin Lung Cancer*. 2021 Feb 4:S1525-7304(21)00023-1.

101. Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, **Besse B**. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. *J Thorac Oncol*. 2021 Feb 27;S1556-0864(21)01745-7.
102. Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, **Besse B**. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. *Ann Oncol*. 2021 May;32(5):620-630.
103. Honoré C, Mir O, Geraud A, Drovetti G, Garcia GCTE, Gustin P, Colomba E, Pilorge S, Matias M, Majer M, Balleyguier C, Azoulay M, **Besse B**, Herve R, Vial G, Ducreux M. Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. *JCO Oncol Pract*. 2021 Feb 23:OP2000525.
104. Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, **Besse B**, Adam J. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. *Eur J Cancer*. 2021 Jan 27;145:221-229.
105. Betsler L, Glorion M, Mordant P, Caramella C, Ghigna MR, **Besse B**, Planchard D, Le Pavec J, Chapelier A, Friard S, Gounant V, Castier Y, Levy A, Mercier O, Fabre D, Fadel E, Pradere P. Cannabis use and lung cancer: time to stop overlooking the problem? *Eur Respir J*. 2021 Jan 28:2004132.
106. Abbar B, De Castelbajac V, Gougis P, Assoun S, Pluvy J, Tesmoingt C, Théou-Anton N, Cazes A, Namour C, Khalil A, Gounant V, **Besse B**, Zalzman G, Brosseau S. Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. *Lung Cancer*. 2021 Feb;152:109-118.
107. Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, **Besse B**. Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2020 Dec 14;12(12):3758.
108. Molina TJ, Bluthgen MV, Chalabreysse L, de Montpréville VT, de Muret A, Dubois R, Hofman V, Lantuejoul S, le Naoures C, Mansuet-Lupo A, Parrens M, Piton N, Rouquette I, Secq V, Girard N, Marx A, **Besse B**. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. *Eur J Cancer*. 2021 Jan;143:158-167.
109. Chalabreysse L, Dubois R, Hofman V, Le Naoures C, Mansuet-Lupo A, de Montpréville VT, De Muret A, Parrens M, Piton N, Rouquette I, Secq V, Singeorzan C, Marx A, Girard N, **Besse B**, Molina TJ. [Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. *Ann Pathol*. 2020 Dec 10:S0242-6498(20)30268-6.
110. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. *N Engl J Med*. 2020 Nov 19;383(21):2018-2029.

111. Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, Halse H, Grynszpan L, Signolle N, Dayris T, Leclerc M, Droin N, de Montpréville V, Mercier O, Validire P, Scoazec JY, Massard C, Chouaib S, Planchard D, Adam J, **Besse B**, Mami-Chouaib F. CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. *Cell Rep Med*. 2020 Oct 20;1(7):100127.
112. Riudavets M, Caramella C, Pradere P, Naltet C, Le Pechoux C, Adam J, Mabile L, Rouleau E, **Besse B**, Planchard D. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. *Clin Lung Cancer*. 2020 Oct 21:S1525-7304(20)30313-2.
113. Subbiah V, Paz-Ares L, **Besse B**, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. *Lung Cancer*. 2020 Dec;150:90-96.
114. Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, Yevich S, Roux C, Mussot S, Delpla A, Varin F, Hakime A, Teriitehau C, Le Péchoux C, Pradère P, Caramella C, **Besse B**, Fadel E, de Baere T. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. *Diagn Interv Imaging*. 2021 Jan;102(1):19-26.
115. De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, Martinez G, Benitez JC, Martín-Romano P, El-Amarti L, Hendriks L, Ferrara R, Naltet C, Lavaud P, Gazzah A, Adam J, Planchard D, Chaput N, **Besse B**. Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). *Cancers (Basel)*. 2020 Sep 30;12(10):2827
116. Recondo G, Mahjoubi L, Maillard A, Loria Y, Bigot L, Facchinetti F, Bahleda R, Gazzah A, Hollebecque A, Mezquita L, Planchard D, Naltet C, Lavaud P, Lacroix L, Richon C, Lovergne AA, De Baere T, Tselikas L, Deas O, Nicotra C, Ngo-Camus M, Frias RL, Solary E, Angevin E, Eggermont A, Olaussen KA, Vassal G, Michiels S, Andre F, Scoazec JY, Massard C, Soria JC, **Besse B**, Friboulet L. Feasibility and first reports of the MATCH-R
117. Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, Nicotra C, Auclin E, Remon J, Morris C, Green E, Massard C, Pérol M, Friboulet L, **Besse B**, Saintigny P. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. *JCO Precis Oncol*. 2020 Apr 2;4:PO.19.00281.
118. Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, **Besse B**, Chaput N. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clin Cancer Res*. 2021 Jan 15;27(2):492-503.

119. Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Ait Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, **Besse B**, Blay JY, Saintigny P, Planchard D. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2020 Dec 1;26(23):6242-6253.
120. Drilon A, Oxnard GR, Tan DSW, Loong HHH, Johnson M, Gainor J, McCoach CE, Gautschi O, **Besse B**, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2020 Aug 27;383(9):813-824.
121. Besson FL, Fernandez B, Faure S, Mercier O, Seferian A, Mignard X, Mussot S, le Pechoux C, Caramella C, Botticella A, Levy A, Parent F, Bulifon S, Montani D, Mitilian D, Fadel E, Planchard D, **Besse B**, Ghigna-Bellinzoni MR, Comtat C, Lebon V, Durand E. 18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. *EJNMMI Res*. 2020 Jul 30;10(1):88.
122. Phan T, Devine C, Laursen ED, Simpson A, Kahn A, Khandhar AP, Mesite S, **Besse B**, Mabery KJ, Flanagan EI, Fox CB. Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response. *Pharmaceuticals (Basel)*. 2020 Jul 28;13(8):168.
123. Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, **Besse B**. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. *Nat Rev Clin Oncol*. 2020 Nov;17(11):707-715.
124. Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, **Besse B**, Rabaglio M, O'Brien MER, Stahel RA. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. *J Thorac Oncol*. 2020 Oct;15(10):1647-1656.
125. Girard N, Greillier L, Zalcman G, Cadranel J, Moro-Sibilot D, Mazières J, Audigier-Valette C, Bennouna J, **Besse B**, Cortot A, Couraud S, Duruisseaux M, Giroux-Leprieur E, Toffart AC, Westeel V, Wislez M; French-Language Society of Pulmonology SPLF French-language Oncology Group. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. *Respir Med Res*. 2020 Nov;78:100769.
126. Desbois M, Béal C, Charrier M, **Besse B**, Meurice G, Cagnard N, Jacques Y, Bécharde D, Cassard L, Chaput N. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment. *J Immunother Cancer*. 2020 Jun;8(1):e000632.

127. Remon J, Swalduz A, Planchard D, Ortiz-Cuaran S, Mezquita L, Lacroix L, Jovelet C, Rouleau E, Leonce C, De Kievit F, Morris C, Jones G, Mercier K, Howarth K, Green E, Pérol M, Saintigny P, **Besse B**. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. *PLoS One*. 2020 Jun 11;15(6):e0234302.
128. Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, Planchard D, Balleyguier C, **Besse B**, Mezquita L, Lassau N, Caramella C. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. *JAMA Oncol*. 2020 Jul 1;6(7):1039-1046.
129. Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, **Besse B**, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. *Lung Cancer*. 2020 Aug;146:6-11.
130. Putora PM, Fischer GF, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman BJ, Troost EGC, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, **Besse B**, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. *Radiother Oncol*. 2020 Aug;149:84-88.
131. Thomas de Montpréville V, Lacroix L, Rouleau E, Mamodaly M, Leclerc J, Tutuianu L, Planchard D, Boulate D, Mercier O, **Besse B**, Fadel É, Ghigna MR. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases. *Ann Diagn Pathol*. 2020 Jun;46:151522.
132. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, **Besse B**, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. *Nat Med*. 2020 May;26(5):665-671.
133. Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, **Besse B**, Soria JC, Friboulet L, Planchard D. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. *Eur J Cancer*. 2020 Jun;132:211-223.
134. Peters S, Shaw AT, **Besse B**, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. *Lung Cancer*. 2020 Jun;144:10-19.
135. Legoupil C, Debievre D, Marabelle A, Michiels S, Kapso R, **Besse B**, Bonastre J. A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. *ERJ Open Res*. 2020 Apr 19;6(2):00174-2019.
136. Dormieux A, Mezquita L, Cournede PH, Remon J, Tazdait M, Lacroix L, Rouleau E, Adam J, Bluthgen MV, Facchinetti F, Tselikas L, Aboubakar F, Naltet C, Lavaud P, Gazzah A, Le Pechoux C, Lassau N, Balleyguier C, Planchard D, **Besse B**, Caramella C. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. *Eur Radiol*. 2020 Sep;30(9):5021-5028.
137. Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hirtet S, Dixmier A, Renault

- PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, **Besse B**. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. *Eur J Cancer*. 2020 May;131:27-36.
138. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, **Besse B**, Marabelle A, Netzer F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. *Ann Oncol*. 2020 Jul;31(7):961-964.
139. Trigo J, Subbiah V, **Besse B**, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020 May;21(5):645-654.
140. Mezquita L, Jové M, Nadal E, Kfoury M, Morán T, Ricordel C, Dhooge M, Tlemsani C, Léna H, Teulé A, Álvarez JV, Raimbourg J, Huret S, Lacroix L, Menéndez M, Saldaña J, Brunet J, Lianes P, Coupier I, Auclin E, Recondo G, Friboulet L, Adam J, Green E, Planchard D, Frébourg T, Capella G, Rouleau E, Lázaro C, Caron O, **Besse B**. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. *J Thorac Oncol*. 2020 Jul;15(7):1232-1239.
141. Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauquil C, Ederhy S, Barreau E, Belkhir R, Berdelou A, Lazarovici J, Chanson P, Izzedine H, Seferian A, Le Pajolec C, Baldini C, Martin-Romano P, Mariette X, Robert C, **Besse B**, Hollebecque A, Varga A, Laghouati S, Mateus C, Voisin AL, Soria JC, Massard C, Marabelle A, Champiat S, Lambotte O. The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. *Eur J Cancer*. 2020 May;130:39-50.
142. Mazieres J, Barlesi F, Rouquette I, Molinier O, **Besse B**, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Huret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ. Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial. *Clin Cancer Res*. 2020 Jul 1;26(13):3172-3181.
143. Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, **Besse B**, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. *Eur J Cancer*. 2020 Apr;129:71-79.
144. **Besse B**, Garrido P, Cortot AB, Johnson M, Murakami H, Gazzah A, Gil M, Bennouna J. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. *Lung Cancer*. 2020 Apr;142:63-69.
145. Levy A, Doyen J, Botticella A, Bourdais R, Achkar S, Giraud P, Du C, Naltet C, Lavaud P, **Besse B**, Pradère P, Mercier O, Caramella C, Planchard D, Deutsch E, Le Péchoux C. [Role of immunotherapy in locally advanced non-small cell lung cancer]. *Cancer Radiother*. 2020 Feb;24(1):67-72.
146. Noël N, Le Roy A, Hot A, Saadoun D, Lazaro E, Lévesque H, Le Gouellec N, Meaux-Ruault N, Nguyen T, Costedoat-Chalumeau N, Amieux B, Fontana A, De



- Gennes C, Fulpin J, Thomas PA, Bluthgen MV, **Besse B**, Lambotte O. Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. *Autoimmun Rev*. 2020 Mar;19(3):102464.
147. Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, **Besse B**. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. *J Thorac Oncol*. 2020 Mar;15(3):383-391.
148. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, **Besse B**, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282.
149. Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, **Besse B**, Molina TJ, Mazières J. Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. *Biomark Res*. 2019 Dec 4;7:28.
150. Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, Jahanzeb M, Suzuki H, **Besse B**, Lopes G. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. *Br J Cancer*. 2020 Feb;122(3):340-347.
151. Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, Caramella C, Deutsch E, Grimaldi S, Adam J, Ammari S, Planchard D, Lebourleux S, **Besse B**. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. *Eur J Nucl Med Mol Imaging*. 2020 May;47(5):1147-1157.